Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Vomiting 3Lymphoma, Mantle-Cell 2Neoplasms 1Nausea 1Lymphoma 1Leukemia, Mast-Cell 1Glioma 1

Interventions

fludarabine phosphate 3midostaurin 2Whole-Body Irradiation 2Therapeutics 2Mycophenolic Acid 2Methotrexate 2Cyclosporine 2Busulfan 2thymoglobulin 1ibrutinib 1hydrocortisone valerate 1fludarabine 1denileukin diftitox 1avapritinib 1Thiotepa 1Tacrolimus 1Sunitinib 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Methylprednisolone Hemisuccinate 1Methylprednisolone Acetate 1Methylprednisolone 1Leucovorin 1Imatinib Mesylate 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Granisetron 1Filgrastim 1Epoetin Alfa 1Enzyme-Linked Immunosorbent Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Mast-Cell × Granisetron × Clear all
NCT00186628 2017-11-28

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Stanford University

Phase 2 Completed
36 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Mast-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡